Abstract 634P
Background
CTS2190 could specifically inhibit type I protein arginine methyltransferases (PRMTs) and significantly reduce intra-tumor asymmetric dimethylarginine (ADMA) level and oncogenic proliferation by epigenetic modulation, RNA splicing, DNA damage as well as remarkable cancer immune activation in various solid and/or hematological cancers. Here we report the dose escalation results from an ongoing first-in-human phase I/II study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of CTS2190 in patients (pts) with advanced solid tumors.
Methods
Eligible pts were enrolled in escalating dose cohorts (60 to 240 mg) administered orally until progression or unacceptable toxicity. The accelerated titration combined with Bayesian optimal interval (BOIN) design was used as the dose escalation schedule.
Results
As of Apr 2, 2024, 15 pts including 10 non-small cell lung cancer (NSCLC), 1 colorectal cancer (CRC),1 triple-negative breast cancer (TNBC), 2 head and neck squamous cell carcinoma (HNSCC) and 1 esophageal squamous cell carcinoma (ESCC) received CTS2190 treatment. Among them, 9 pts received ≥3 lines of prior therapy. Treatment-related adverse events (TRAEs) of ≥Grade 3 were platelet count decreased (33.3%), amylase increased (6.7%) and blood creatine phosphokinase increased (6.7%). Dose-limiting toxicity (DLT) was observed in 1 pt (in 240 mg) who continued treatment after dose reduction. No TRAEs led to treatment discontinuation or death. Of the 10 response-evaluable pts (>60 mg), the objective response rate (ORR) and disease control rate (DCR) were 20.0% and 70.0% respectively. In the subset of NSCLC pts, the ORR and DCR were 40.0% and 60.0% respectively. Exposure of CTS2190 increased proportionally with increasing dose. Time- and dose-dependent pharmacodynamics (PD) changes in circulating free ADMA, monomethylarginine (MMA) and symmetric dimethylarginine (SDMA) were also observed.
Conclusions
CTS2190 was well tolerated and showed encouraging antitumor activities in advanced and/or metastatic solid tumors, including NSCLC, TNBC, HNSCC and ESCC. Further investigation of CTS2190 in larger pts population is ongoing including biomarker exploration.
Clinical trial identification
NCT06224387.
Editorial acknowledgement
Legal entity responsible for the study
CytosinLab Therapeutics Co., Ltd.
Funding
CytosinLab Therapeutics Co., Ltd.
Disclosure
J. Miao, Y. Mi, S. Xing, H. Wu: Financial Interests, Personal and Institutional, Full or part-time Employment: CytosinLab Therapeutics Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
723P - A phase II study of cadonilimab plus chemotherapy in persistent recurrent/ metastatic cervical cancer patients who failed previous immuno/chemotherapy
Presenter: Li Xiaoling Li
Session: Poster session 01
724P - Preliminary outcomes from a phase Ib/II study of the highly potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced cervical cancer
Presenter: Guiling Li
Session: Poster session 01
725P - Treatment of patients with metastatic or relapsed cervical cancer: Results from a quality assurance program of the AGO Study Group
Presenter: Dominik Denschlag
Session: Poster session 01
726P - Efficacy and safety of pembrolizumab plus olaparib combination therapy in recurrent cervical cancer progressed on platinum-based chemotherapy: Results from the phase II trial of GOTIC-025
Presenter: Kosei Hasegawa
Session: Poster session 01
727P - Real-world efficacy and safety of cadonilimab in recurrent or metastatic cervical cancer: A multicenter retrospective analysis in China
Presenter: Yang Sun
Session: Poster session 01
Resources:
Abstract
728P - Chemotherapy plus tislelizumab in young patients with cervical cancer preserve fertility: A phase II study
Presenter: Danbo Wang
Session: Poster session 01
729P - Patterns of survivorship care of cervical cancer patients with or without HIV infection in Botswana 2015-2022
Presenter: Sheldon Amoo-Mitchual
Session: Poster session 01
730P - Validation of circulating tumor DNA for prognostication and monitoring in metastatic endometrial carcinoma: Ancillary results from the phase II randomized GINECO trial UTOLA
Presenter: Guillaume Beinse
Session: Poster session 01
731P - Post-progression survival outcomes in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial who received follow-up immunotherapy
Presenter: Mansoor Raza Mirza
Session: Poster session 01
732P - Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E
Presenter: Stephanie Blank
Session: Poster session 01